loader
Please Wait
Applying Filters...
menu
    • menu

    Digital Content for RLY-4008

    Client Email Product
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Virtual Booth

    Contact Supplier

    Axplora- The partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.

    Virtual Booth

    Contact Supplier

    Menu

    RLY-4008

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Lirafugratinib Elicits Durable Responses Across Several FGFR2+ Solid Tumors
    Lirafugratinib Elicits Durable Responses Across Several FGFR2+ Solid Tumors

    13 Oct 2023

    // ONCLIVE

    https://www.onclive.com/view/lirafugratinib-elicits-durable-responses-across-several-fgfr2-solid-tumors

    ONCLIVE
    13 Oct 2023
    Share Share
    Relay Therapeutics Announces RLY-4008 Data Showing Durable Responses Across Multiple FGFR2-Altered Solid Tumors
    Relay Therapeutics Announces RLY-4008 Data Showing Durable Responses Across Multiple FGFR2-Altered Solid Tumors

    12 Oct 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/10/12/2759649/0/en/Relay-Therapeutics-Announces-Initial-RLY-4008-lirafugratinib-Data-Demonstrating-Durable-Responses-Across-Multiple-FGFR2-Altered-Solid-Tumors.html

    GLOBENEWSWIRE
    12 Oct 2023
    Share Share